Nintedanib

Status
Phase 3
Condition
Other Related Conditions
Intervention Type
Oral Drug
Funder Type
Industry
The main objective is to assess long term safety of treatment with oral nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).

NCT03313180
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >